Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Income from Continuing Operations (2016 - 2020)

Syndax Pharmaceuticals (SNDX) has disclosed Income from Continuing Operations for 6 consecutive years, with 19860000.0 as the latest value for Q4 2020.

  • For Q4 2020, Income from Continuing Operations fell 39.81% year-over-year to 19860000.0; the TTM value through Dec 2020 reached 71423000.0, down 24.13%, while the annual FY2025 figure was 250360000.0, 20.16% up from the prior year.
  • Income from Continuing Operations hit 19860000.0 in Q4 2020 for Syndax Pharmaceuticals, roughly flat from 19853000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 8358000.0 in Q2 2016 and bottomed at 19860000.0 in Q4 2020.
  • Average Income from Continuing Operations over 5 years is 15409000.0, with a median of 15067500.0 recorded in 2017.
  • Year-over-year, Income from Continuing Operations plummeted 145.93% in 2016 and then grew 26.52% in 2019.
  • Syndax Pharmaceuticals' Income from Continuing Operations stood at 10873000.0 in 2016, then crashed by 74.99% to 19027000.0 in 2017, then dropped by 1.61% to 19333000.0 in 2018, then increased by 26.52% to 14205000.0 in 2019, then crashed by 39.81% to 19860000.0 in 2020.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 19860000.0, 19853000.0, and 16610000.0 for Q4 2020, Q3 2020, and Q2 2020 respectively.